6-氟-1-甲基-1H-吲哚-2-甲酸甲酯 | 550349-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-氟-1-甲基-1H-吲哚-2-甲酸甲酯
• 英文名称: methyl 6-fluoro-1-methyl-1H-indole-2-carboxylate
• 英文别名: methyl 6-fluoro-1-methylindole-2-carboxylate
• CAS: 550349-31-0
• 化学式: C₁₁H₁₀FNO₂
• 分子量: 207.204
• InChiKey: QASNBMUHZSKGTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-氟-1-甲基-1H-吲哚-2-甲酸甲酯 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以75.08 %的产率得到6-fluoro-1-methyl-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  WO2023/287704

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氟吲哚-2-羧酸 在 sodium hydride 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 6-氟-1-甲基-1H-吲哚-2-甲酸甲酯
  参考文献：
  名称：

  WO2023/287704

  摘要：

  公开号：

文献信息

• 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use
  申请人：Burnier Philippe

  公开号：US20050096321A1

  公开（公告）日：2005-05-05

  The invention concerns compounds of general formula (I), wherein: X represents a hydrogen or halogen atom; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group; R 2 and R 3 , represent each, independently of each other, a hydrogen atom or a (C 1 -C 4 )alkyl group, or R 2 and R 3 form, with the atom which bears them, a pyrrolidinyl, piperidinyl, morpholinyl or 4-alkylpiperazinyl group; and Het represents a heteroaromatic group of pyridinyl, 1-oxidopyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl, pyridazinyl type, the heteroaromatic group may represent one or several halogen atoms and/or one or several (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxyl groups; in the form of bases, addition salts to acids, solvates or hydrates. The invention also concerns pharmaceutical compositions containing same, methods for preparing same and synthesis intermediates.

  本发明涉及通式（I）的化合物，其中：X表示氢原子或卤素原子；R1表示氢原子或（C1-C4）烷基基团；R2和R3分别独立地表示氢原子或（C1-C4）烷基基团，或R2和R3与带有它们的原子形成吡咯烷基，哌啶基，吗啉基或4-烷基哌嗪基团；Het表示吡啶基，1-氧代吡啶基，喹啉基，异喹啉基，嘧啶基，吡嗪基，吡啶嗪基等杂环芳基，该杂环芳基可以表示一个或多个卤素原子和/或一个或多个（C1-C4）烷基，（C1-C4）烷氧基团；以碱，酸加成盐，溶剂合物或水合物的形式存在。本发明还涉及含有这些化合物的制药组合物，制备这些化合物的方法和合成中间体。
• 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments
  申请人：Froissant Jacques

  公开号：US20050124615A1

  公开（公告）日：2005-06-09

  The invention provides compounds of general formula (I) in which X represents a hydrogen or halogen atom; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group; R 2 and R 3 each independently of one another represent a hydrogen atom or a (C 1 -C 4 )alkyl group, or else R 2 and R 3 , together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C 1 -C 4 )alkylpiperazinyl group; and Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C 1 -C 4 )alkyl and/or (C 1 -C 4 )alkoxy groups; in the form of bases, addition salts with acids, solvates or hydrates; the pharmaceutical compositions comprising them, processes for preparing them, and synthesis intermediates.

  本发明提供了通式（I）的化合物，其中X代表氢原子或卤素原子；R1代表氢原子或（C1-C4）烷基基团；R2和R3各自独立地表示氢原子或（C1-C4）烷基基团，或者R2和R3与它们所带的氮原子一起形成吡咯烷基，哌啶基，吗啉基或4-（C1-C4）烷基哌嗪基基团；Het表示吡啶基，喹啉基，异喹啉基，嘧啶基，吡嗪基或吡嗪啉基等杂环芳基，可以携带一个或多个卤素原子和/或一个或多个（C1-C4）烷基和/或（C1-C4）烷氧基团；以碱，酸盐，溶剂合物或水合物的形式存在；以及包括它们的制药组合物，制备它们的过程和合成中间体。
• 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
  申请人：BURNIER Philippe

  公开号：US20060241116A1

  公开（公告）日：2006-10-26

  A subject-matter of the invention is the compounds of general formula (I) in which X represents a hydrogen or halogen atom; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group; R 2 and R 3 each represent, independently of one another, a hydrogen atom or a (C 1 -C 4 )alkyl group or else R 2 and R 3 form, with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl, morpholinyl or 4-alkylpiperazinyl group; and Het represents a heteroaromatic group of pyridinyl, 1-oxidopyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type, it being possible for the heteroaromatic group to carry one or more halogen atoms and/or one or more (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy groups; in the form of bases, of addition salts with acids, of solvates or of hydrates, the pharmaceutical compositions comprising them, processes for their preparation and synthetic intermediates.

  一项发明的主题是具有一般式（I）的化合物，其中X代表氢或卤素原子；R1代表氢原子或（C1-C4）烷基；R2和R3各自独立地表示氢原子或（C1-C4）烷基，或者R2和R3与它们所携带的氮原子形成吡咯烷基，哌啶基，吗啉基或4-烷基哌嗪基；Het表示吡啶基，1-氧代吡啶基，喹啉基，异喹啉基，嘧啶基，吡嗪基或吡嗪啉基的杂环芳基，其中杂环芳基可以携带一个或多个卤素原子和/或一个或多个（C1-C4）烷基或（C1-C4）烷氧基；以碱，酸盐，溶剂化合物或水合物的形式存在，包括它们的制药组合物，它们的制备过程和合成中间体。
• 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
  申请人：FROISSANT Jacques

  公开号：US20070219202A1

  公开（公告）日：2007-09-20

  The invention discloses and claims therapeutic uses of compounds of general formula (I) Wherein X, R 1 , R 2 and R 3 are as described herein. The invention further discloses processes for preparing them, and novel intermediates therefor.

  该发明公开并声明了通式（I）化合物的治疗用途，其中X，R1，R2和R3如本文所述。该发明还公开了制备它们的过程以及新的中间体。
• 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments
  申请人：Sanofi-Aventis

  公开号：US07235554B2

  公开（公告）日：2007-06-26

  The invention provides compounds of general formula (I) in which X represents a hydrogen or halogen atom; R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 and R3 each independently of one another represent a hydrogen atom or a (C1-C4)alkyl group, or else R2 and R3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C1-C4)alkylpiperazinyl group; and Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C1-C4)alkyl and/or (C1-C4)alkoxy groups; in the form of bases, addition salts with acids, solvates or hydrates; the pharmaceutical compositions comprising them, processes for preparing them, and synthesis intermediates.

  本发明提供了一般式（I）的化合物，其中X代表氢或卤素原子；R1代表氢原子或（C1-C4）烷基；R2和R3各自独立地代表氢原子或（C1-C4）烷基，或者R2和R3与它们所带的氮原子一起形成吡咯烷基、哌啶基、吗啉基或4-（C1-C4）烷基哌嗪基；Het代表吡啶基、喹啉基、异喹啉基、嘧啶基、吡嗪基或吡啶并嘧啶基等杂环芳基，可以携带一个或多个卤素原子和/或一个或多个（C1-C4）烷基和/或（C1-C4）烷氧基团；以碱、酸加合物、溶剂合物或水合物的形式存在；还包括含有它们的制药组合物、制备它们的方法以及合成中间体。